143 related articles for article (PubMed ID: 23053402)
21. Derivation of a new equation for estimating creatinine clearance by using fat-free mass and serum creatinine concentration in Korean patients with type 2 diabetes mellitus.
Lee EK; Cho YM; Kim JT; Koo BK; Cho HY; Ku YH; Park KS; Jang HC; Kim SY; Lee HK
Diabetes Res Clin Pract; 2009 Jan; 83(1):44-9. PubMed ID: 19027979
[TBL] [Abstract][Full Text] [Related]
22. Renal function impairment in cervical cancer patients treated with cisplatin-based chemoradiation: A review of medical records in a Zimbabwean outpatient department.
Manyau PMC; Mabeka M; Mudzviti T; Kadzatsa W; Nyamhunga A
PLoS One; 2021; 16(2):e0245383. PubMed ID: 33626044
[TBL] [Abstract][Full Text] [Related]
23. Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy.
Cavalcanti E; Barchiesi V; Cerasuolo D; Di Paola F; Cantile M; Cecere SC; Pignata S; Morabito A; Costanzo R; Di Maio M; Perrone F
Anal Cell Pathol (Amst); 2016; 2016():4918325. PubMed ID: 28078200
[No Abstract] [Full Text] [Related]
24. Telmisartan Exacerbates Cisplatin-Induced Nephrotoxicity in a Mouse Model.
Hosoda A; Matsumoto Y; Toriyama Y; Tsuji T; Yoshida Y; Masamichi S; Kohno T
Biol Pharm Bull; 2020; 43(9):1331-1337. PubMed ID: 32879207
[TBL] [Abstract][Full Text] [Related]
25. Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone.
Merouani A; Davidson SA; Schrier RW
Am J Nephrol; 1997; 17(1):53-8. PubMed ID: 9057954
[TBL] [Abstract][Full Text] [Related]
26. [Nephrotoxicity of a Short Hydration Method for the Cisplatin Regimen in Patients with Gastric Cancer].
Kishi K; Saito T; Mikamori M; Ohtsuka M; Furukawa K; Suzuki Y; Tei M; Tanemura M; Akamatsu H
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2069-2071. PubMed ID: 30692287
[TBL] [Abstract][Full Text] [Related]
27. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine.
Rashid ST; Salman M; Agarwal S; Hamilton G
Eur J Vasc Endovasc Surg; 2006 Sep; 32(3):294-9. PubMed ID: 16716614
[TBL] [Abstract][Full Text] [Related]
28. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
Yogi S; Ikeuchi T; Kai Y
Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
[TBL] [Abstract][Full Text] [Related]
29. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
Jhaveri KD; Flombaum C; Shah M; Latcha S
J Oncol Pharm Pract; 2012 Mar; 18(1):140-7. PubMed ID: 22392964
[TBL] [Abstract][Full Text] [Related]
30. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients.
Moon HH; Seo KW; Yoon KY; Shin YM; Choi KH; Lee SH
World J Gastroenterol; 2011 Aug; 17(30):3510-7. PubMed ID: 21941418
[TBL] [Abstract][Full Text] [Related]
31. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
[TBL] [Abstract][Full Text] [Related]
32. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
[TBL] [Abstract][Full Text] [Related]
33. Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin.
Maeda A; Ando H; Ura T; Muro K; Aoki M; Saito K; Kondo E; Takahashi S; Ito Y; Mizuno Y; Fujimura A
Anticancer Res; 2017 Sep; 37(9):5235-5239. PubMed ID: 28870959
[TBL] [Abstract][Full Text] [Related]
34. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
Hotta K; Takigawa N; Hisamoto-Sato A; Ichihara E; Kudo K; Uchida K; Yanase-Nakamura K; Tanaka H; Kato Y; Tabata M; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2013 Nov; 43(11):1115-23. PubMed ID: 24082005
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer.
Schild SE; Wong WW; Vora SA; Halyard MY; Wheeler RH
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):729-34. PubMed ID: 12377324
[TBL] [Abstract][Full Text] [Related]
36. Protective effect of royal jelly and green tea extracts effect against cisplatin-induced nephrotoxicity in mice: a comparative study.
Yapar K; Cavuşoğlu K; Oruç E; Yalçin E
J Med Food; 2009 Oct; 12(5):1136-42. PubMed ID: 19857080
[TBL] [Abstract][Full Text] [Related]
37. Long-term evolution of renal function in patients with ovarian cancer after whole abdominal irradiation with or without preceding cisplatin.
Schneider DP; Marti HP; Von Briel C; Frey FJ; Greiner RH
Ann Oncol; 1999 Jun; 10(6):677-83. PubMed ID: 10442190
[TBL] [Abstract][Full Text] [Related]
38. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
Prasaja Y; Sutandyo N; Andrajati R
Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
[TBL] [Abstract][Full Text] [Related]
39. [Value of creatinine clearance rate estimated based on serum cystatin C in patients with acute kidney injury].
Hu JT; Xie XL; Tang ZH; Li CQ; Zhou HW
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Sep; 24(9):534-7. PubMed ID: 22938661
[TBL] [Abstract][Full Text] [Related]
40. Effect of combination sildenafil and gemfibrozil on cisplatin-induced nephrotoxicity; role of heme oxygenase-1.
Behiry S; Rabie A; Kora M; Ismail W; Sabry D; Zahran A
Ren Fail; 2018 Nov; 40(1):371-378. PubMed ID: 29707997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
